BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 36071449)

  • 1. HIV-1 bispecific antibody iMab-N6 exhibits enhanced breadth but not potency over its parental antibodies iMab and N6.
    Moshoette T; Papathanasopoulos MA; Killick MA
    Virol J; 2022 Sep; 19(1):143. PubMed ID: 36071449
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Engineering and characterising a novel, highly potent bispecific antibody iMab-CAP256 that targets HIV-1.
    Moshoette T; Ali SA; Papathanasopoulos MA; Killick MA
    Retrovirology; 2019 Nov; 16(1):31. PubMed ID: 31703699
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bispecific antibodies directed to CD4 domain 2 and HIV envelope exhibit exceptional breadth and picomolar potency against HIV-1.
    Pace CS; Song R; Ochsenbauer C; Andrews CD; Franco D; Yu J; Oren DA; Seaman MS; Ho DD
    Proc Natl Acad Sci U S A; 2013 Aug; 110(33):13540-5. PubMed ID: 23878231
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rational design and characterization of the novel, broad and potent bispecific HIV-1 neutralizing antibody iMabm36.
    Sun M; Pace CS; Yao X; Yu F; Padte NN; Huang Y; Seaman MS; Li Q; Ho DD
    J Acquir Immune Defic Syndr; 2014 Aug; 66(5):473-83. PubMed ID: 24853313
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Potential of conventional & bispecific broadly neutralizing antibodies for prevention of HIV-1 subtype A, C & D infections.
    Wagh K; Seaman MS; Zingg M; Fitzsimons T; Barouch DH; Burton DR; Connors M; Ho DD; Mascola JR; Nussenzweig MC; Ravetch J; Gautam R; Martin MA; Montefiori DC; Korber B
    PLoS Pathog; 2018 Mar; 14(3):e1006860. PubMed ID: 29505593
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Broad and potent bispecific neutralizing antibody gene delivery using adeno-associated viral vectors for passive immunization against HIV-1.
    Li S; Qiao Y; Jiang S; Wang B; Kong W; Shan Y
    J Control Release; 2021 Oct; 338():633-643. PubMed ID: 34509584
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Distinct HIV-1 Neutralization Potency Profiles of Ibalizumab-Based Bispecific Antibodies.
    Song R; Pace C; Seaman MS; Fang Q; Sun M; Andrews CD; Wu A; Padte NN; Ho DD
    J Acquir Immune Defic Syndr; 2016 Dec; 73(4):365-373. PubMed ID: 27792681
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Bispecific Antibody That Simultaneously Recognizes the V2- and V3-Glycan Epitopes of the HIV-1 Envelope Glycoprotein Is Broader and More Potent than Its Parental Antibodies.
    Davis-Gardner ME; Alfant B; Weber JA; Gardner MR; Farzan M
    mBio; 2020 Jan; 11(1):. PubMed ID: 31937648
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combinations of Single Chain Variable Fragments From HIV Broadly Neutralizing Antibodies Demonstrate High Potency and Breadth.
    van Dorsten RT; Wagh K; Moore PL; Morris L
    Front Immunol; 2021; 12():734110. PubMed ID: 34603312
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety, tolerability, pharmacokinetics, and immunological activity of dual-combinations and triple-combinations of anti-HIV monoclonal antibodies PGT121, PGDM1400, 10-1074, and VRC07-523LS administered intravenously to HIV-uninfected adults: a phase 1 randomised trial.
    Sobieszczyk ME; Mannheimer S; Paez CA; Yu C; Gamble T; Theodore DA; Chege W; Yacovone M; Hanscom B; Heptinstall J; Seaton KE; Zhang L; Miner MD; Eaton A; Weiner JA; Mayer K; Kalams S; Stephenson K; Julg B; Caskey M; Nussenzweig M; Gama L; Barouch DH; Ackerman ME; Tomaras GD; Huang Y; Montefiori D;
    Lancet HIV; 2023 Oct; 10(10):e653-e662. PubMed ID: 37802566
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting the HIV-1 Spike and Coreceptor with Bi- and Trispecific Antibodies for Single-Component Broad Inhibition of Entry.
    Khan SN; Sok D; Tran K; Movsesyan A; Dubrovskaya V; Burton DR; Wyatt RT
    J Virol; 2018 Sep; 92(18):. PubMed ID: 29976677
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Complementary Roles of Antibody Heavy and Light Chain Somatic Hypermutation in Conferring Breadth and Potency to the HIV-1-Specific CAP256-VRC26 bNAb Lineage.
    Sacks D; Wiehe K; Morris L; Moore PL
    J Virol; 2022 May; 96(10):e0027022. PubMed ID: 35510865
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Double and Triple Combinations of Broadly Neutralizing Antibodies Provide Efficient Neutralization of All HIV-1 Strains from the Global Panel.
    Kochina EA; Urusov FA; Kruglov AA; Glazkova DV; Shipulin GA; Bogoslovskaya EV
    Viruses; 2022 Aug; 14(9):. PubMed ID: 36146719
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bispecific Antibodies Targeting Different Epitopes on the HIV-1 Envelope Exhibit Broad and Potent Neutralization.
    Asokan M; Rudicell RS; Louder M; McKee K; O'Dell S; Stewart-Jones G; Wang K; Xu L; Chen X; Choe M; Chuang G; Georgiev IS; Joyce MG; Kirys T; Ko S; Pegu A; Shi W; Todd JP; Yang Z; Bailer RT; Rao S; Kwong PD; Nabel GJ; Mascola JR
    J Virol; 2015 Dec; 89(24):12501-12. PubMed ID: 26446600
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sensitivity to Broadly Neutralizing Antibodies of Recently Transmitted HIV-1 Clade CRF02_AG Viruses with a Focus on Evolution over Time.
    Stefic K; Bouvin-Pley M; Essat A; Visdeloup C; Moreau A; Goujard C; Chaix ML; Braibant M; Meyer L; Barin F
    J Virol; 2019 Jan; 93(2):. PubMed ID: 30404804
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Single-Chain Variable Fragments of Broadly Neutralizing Antibodies Prevent HIV Cell-Cell Transmission.
    van Dorsten RT; Reh L; Trkola A; Morris L; Moore PL
    J Virol; 2022 Feb; 96(4):e0193421. PubMed ID: 34935437
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HIV Broadly Neutralizing Antibodies Expressed as IgG3 Preserve Neutralization Potency and Show Improved Fc Effector Function.
    Richardson SI; Ayres F; Manamela NP; Oosthuysen B; Makhado Z; Lambson BE; Morris L; Moore PL
    Front Immunol; 2021; 12():733958. PubMed ID: 34566999
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Somatic hypermutation to counter a globally rare viral immunotype drove off-track antibodies in the CAP256-VRC26 HIV-1 V2-directed bNAb lineage.
    Sacks D; Bhiman JN; Wiehe K; Gorman J; Kwong PD; Morris L; Moore PL
    PLoS Pathog; 2019 Sep; 15(9):e1008005. PubMed ID: 31479499
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HIV-1 Subtype C-Infected Children with Exceptional Neutralization Breadth Exhibit Polyclonal Responses Targeting Known Epitopes.
    Ditse Z; Muenchhoff M; Adland E; Jooste P; Goulder P; Moore PL; Morris L
    J Virol; 2018 Sep; 92(17):. PubMed ID: 29950423
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterisation of a highly potent and near pan-neutralising anti-HIV monoclonal antibody expressed in tobacco plants.
    Moore CM; Grandits M; Grünwald-Gruber C; Altmann F; Kotouckova M; Teh AY; Ma JK
    Retrovirology; 2021 Jun; 18(1):17. PubMed ID: 34183026
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.